Delivery Order SPE2DB25D7067-SPE2DB25FSVPT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,903.80 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5ML) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,579.74 to AmerisourceBergen Drug Corp for the supply of Menquadfi vial (0.5mL) under a firm fixed price, non-set-aside contract. The award was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania will serve as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,656.00 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5mL) on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5ML) with a ceiling value of $8,254.21 under a firm fixed-price contract type. The award was made on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a competitively awarded, non-set-aside delivery order issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of MENQUADFI vial 0.5ML, a meningococcal vaccine product. The contract is valued at $2,179.32 with a firm fixed price structure and an ultimate completion date of July 30, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $2,905.76 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order represents a non-competitive child award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $1 billion ceiling through December 2026. The product will be performed at the contractor's...
- The Defense Logistics Agency awarded a $1,452.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Menquadfi vial 0.5ml, a meningococcal vaccine product. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen will perform work from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a $15,255.24 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Menquadfi vial 0.5ML, a meningococcal vaccine product. The delivery order, which represents a child contract action under a larger vehicle, is scheduled for completion by August 19, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $2,179.32 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without set-aside designation, reflects a competitively awarded transaction under the company's broader pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $7,484.58 to AmerisourceBergen Drug Corp for MENQUADFI vial 0.5ML on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price contract represents a pharmaceutical supply delivery to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and falls under a delivery order contract type,...
- SPE2DB25D7067Indefinite Delivery Contract
- SPE2DB25D7067-SPE2DB25FSVPTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,264.50 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5mL) with a firm fixed price arrangement. The award was made on August 19, 2025, with an ultimate completion date of August 20, 2025, and represents a non-set-aside, competitively awarded procurement. Performance will be executed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total contract value of $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial federal contract portfolio with the Defense Logistics Agency focused on supplying pharmaceutical products and medical supplies to support military and veteran healthcare systems. The Menquadfi vaccine product supplied under this order supports the Defense Health Agency's medical procurement requirements. The company's demonstrated capability to fulfill federal medical supply needs across multiple therapeutic domains, combined with its extensive IDC vehicle with DLA, positions it as a critical vendor for federal pharmaceutical distribution and medical supply chain support.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 8/19/25 |